☆ 4.7 Article

Multicenter Experience with Neoadjuvant Therapy in Melanoma Highlights Heterogeneity in Contemporary Practice

ANNALS OF SURGERY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Surgery

Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer A Multicenter Propensity Matched Study

Berend J. van der Wilk et al.

Summary: In this retrospective study, the overall survival and progression-free survival of esophageal cancer patients with clinically complete response undergoing active surveillance or immediate surgery were not significantly different. Active surveillance with postponed surgery for recurrent disease did not result in a higher rate of distant dissemination or more severe adverse postoperative outcomes.

ANNALS OF SURGERY (2021)

添加到收藏夹

Review Oncology

Neoadjuvant immunotherapy for melanoma

Ann Y. Lee et al.

Summary: Clinical trials have shown the effectiveness of immunotherapy, particularly checkpoint inhibitors, in treating patients with metastatic melanoma. Recent reports indicate improved survival in high-risk resectable melanoma patients with adjuvant immunotherapy. Growing interest in neoadjuvant immunotherapy for high-risk resectable melanoma has been driven by early evidence of significant efficacy.

JOURNAL OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

Alexander M. Menzies et al.

Summary: A pooled analysis of neoadjuvant immunotherapy trials in melanoma revealed that the degree of pathological response is correlated with patient survival, serving as a potential surrogate marker for long-term outcomes. Patients with pathological complete response (pCR) after immunotherapy showed significantly improved recurrence-free survival (RFS) and overall survival (OS) compared to those without pCR. Pathological response, particularly pCR, could be an early surrogate endpoint for clinical trials and a new benchmark for development and approval in melanoma.

NATURE MEDICINE (2021)

添加到收藏夹

Meeting Abstract Oncology

Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.

Rodabe Navroze Amaria et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanoma

Zeynep Eroglu et al.

PIGMENT CELL & MELANOMA RESEARCH (2020)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial

Han-Byoel Lee et al.

BREAST CANCER RESEARCH AND TREATMENT (2020)

添加到收藏夹

Review Oncology

LAG-3: from molecular functions to clinical applications

Takumi Maruhashi et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

Alexander C. Huang et al.

NATURE MEDICINE (2019)

添加到收藏夹

Review Oncology

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

Rodabe N. Amaria et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Elisa A. Rozeman et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Caroline Robert et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Review Oncology

Updates in adjuvant systemic therapy for melanoma

Minyoung Kwak et al.

JOURNAL OF SURGICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

M. T. Tetzlaff et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

Margaret K. Callahan et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Rodabe N. Amaria et al.

NATURE MEDICINE (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

Christian U. Blank et al.

NATURE MEDICINE (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Is earlier better for melanoma checkpoint blockade?

Caroline Robert

NATURE MEDICINE (2018)

添加到收藏夹

Review Oncology

Rationale for Complete Metastasectomy in Patients With Stage IV Metastatic Melanoma

David W. Ollila et al.

JOURNAL OF SURGICAL ONCOLOGY (2011)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.